Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1490
Abstract: Key Points Question Are frontline therapies recommended for malignant pleural mesothelioma (MPM) associated with patient benefits? Findings In this comparative effectiveness study of 1501 participants, the statistical robustness of the Mesothelioma Cisplatin Pemetrexed Study (MPS),… read more here.
Keywords: malignant pleural; clinical trials; frontline therapies; pleural mesothelioma ... See more keywords
Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.4261
Abstract: Key Points Question What is the association of social determinants of health (SDOHs) with treatment and survival of patients with malignant pleural mesothelioma? Findings In this nationwide cohort study of 1389 adults with operable mesothelioma,… read more here.
Keywords: malignant pleural; pleural mesothelioma; mesothelioma; social determinants ... See more keywords
Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202100149
Abstract: Malignant pleural effusion (MPE) remains a treatment bottleneck in advanced lung cancer, due to its complicated microenvironments and "cold" immunity. Therefore, the search for therapeutic drugs to transform MPE to functionally "hot" one could advance… read more here.
Keywords: microenvironment; mpe; malignant pleural; pleural effusion ... See more keywords
Mesothelioma in situ with regressive malignant pleural effusion and an unexpected evolution: A case report.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of industrial medicine"
DOI: 10.1002/ajim.23358
Abstract: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that originates from hyperplasia and metaplasia of the mesothelial cells that cover the pleural cavity. Previous exposure to asbestos is the main risk factor. Since MPM is… read more here.
Keywords: pleural effusion; malignant pleural; mesothelioma; case ... See more keywords
Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5174
Abstract: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. read more here.
Keywords: malignant pleural; pleural mesothelioma; alternative splicing; prognostic risk ... See more keywords
Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.25053
Abstract: Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy with a poor prognosis. Because of this tumor rarity and overlapping histologic features with other malignancy types, the histopathological findings and diagnostic immunohistochemical workup are… read more here.
Keywords: diagnostic criteria; malignant pleural; updates immunohistochemical; pleural mesothelioma ... See more keywords
Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.25143
Abstract: To confirm the predictive value of targeted therapies for oncogenic driver gene mutations detected in malignant pleural effusion (MPE) cell blocks from patients with advanced non‐small cell lung cancer (NSCLC). read more here.
Keywords: cell; non small; pleural effusion; malignant pleural ... See more keywords
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30412
Abstract: It has recently been reported that a large proportion of human malignant pleural mesothelioma (MPM) cell lines and patient tissue samples present high expression of the c‐MYC oncogene. This gene drives several tumorigenic processes and… read more here.
Keywords: mesothelioma; otx015; inhibitor otx015; bromodomain inhibitor ... See more keywords
Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non–small‐cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Laboratory Analysis"
DOI: 10.1002/jcla.22943
Abstract: Limited data are available for the diagnostic value, and the diagnostic sensitivity and specificity of pleural fluid periostin (pPOSTN) and serum periostin (sPOSTN) in malignant pleural effusion (MPE) caused by non–small‐cell lung cancer (NSCLC). read more here.
Keywords: periostin; malignant pleural; diagnostic value; pleural fluid ... See more keywords
IL‐26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4+IL‐22+ T‐cell differentiation and inhibiting CD8+ T‐cell cytotoxicity
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.1ma0221-479rr
Abstract: IL‐26 is a newly discovered IL‐10 cytokine family member mainly secreted by Th17 cells. However, the relationship between IL‐26 and lung cancer remains unclear. The present study reported that IL‐26 is involved in the production… read more here.
Keywords: mpe; cd4 cells; cd4; pleural effusion ... See more keywords
Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of surgical oncology"
DOI: 10.1002/jso.27243
Abstract: BACKGROUND Pleural mesothelioma is rare cancer linked to asbestos exposure. Previous research has indicated that female individuals have better survival than male individuals, but this has never been examined in the Surveillance, Epidemiology, and End… read more here.
Keywords: malignant pleural; seer medicare; pleural mesothelioma; analysis ... See more keywords